The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2018 | Novel agents in AML: highlights from EHA 2018
The development of novel agents to treat acute myeloid leukemia (AML) is constantly revolutionizing the field. In this video, Christoph Röllig, MD, of the University Hospital Carl Gustav Carus, Dresden, Germany, speaks about his highlights from the novel agent discussions held at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. These vary from new immunotherapeutic treatments to FLT3 inhibitors, to small molecules like venetoclax and glasdegib, all of which have yielded positive results in clinical trials.
